Literature DB >> 11414801

Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector.

J Kovarik1, M Gaillard, X Martinez, P Bozzotti, P H Lambert, T F Wild, C A Siegrist.   

Abstract

Although initially developed in adult animals, novel viral vectors expressing recombinant measles antigens must eventually prove their success in the early life setting, where the efficacy of the currently used live-attenuated measles virus vaccine is limited. The immunological requirements for vaccine candidates include the generation of protective antibody responses as well as the induction of Th1 and cytotoxic T lymphocytes (CTL) responses, which is challenging in the neonatal setting. Here, we report that young BALB/c mice immunized with a single dose of a vaccinia-based NYVAC(K1L) vector generate adult-like antihemagglutinin (HA) antibody responses as well as adult-like Th1 and CTL responses. Despite this strong immunogenicity in early life, antibody responses (but not T-cell responses) to a single dose of NYVAC(K1L)-HA remained susceptible to inhibition by preexisting measles antibodies, calling for use of prime-boost strategies. NYVAC(K1L)-HA is the first attenuated live viral vector demonstrated as capable of inducing adult-like antibody, Th1, and CTL responses against measles in an early life murine immunization model, a capacity previously only reported for measles DNA vaccines. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414801     DOI: 10.1006/viro.2001.0945

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Authors:  Roudaina Nasser; Mireia Pelegrin; Henri-Alexandre Michaud; Marc Plays; Marc Piechaczyk; Laurent Gros
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

2.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

3.  Yersinia enterocolitica promotes robust mucosal inflammatory T-cell immunity in murine neonates.

Authors:  Andrea Echeverry; Shinobu Saijo; Kurt Schesser; Becky Adkins
Journal:  Infect Immun       Date:  2010-06-01       Impact factor: 3.441

4.  Murine neonates develop vigorous in vivo cytotoxic and Th1/Th2 responses upon exposure to low doses of NIMA-like alloantigens.

Authors:  Shannon J Opiela; Robert B Levy; Becky Adkins
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

Review 5.  Immunization of pregnant women: Future of early infant protection.

Authors:  Azure N Faucette; Michael D Pawlitz; Bo Pei; Fayi Yao; Kang Chen
Journal:  Hum Vaccin Immunother       Date:  2015-09-14       Impact factor: 3.452

Review 6.  Maternal vaccination: moving the science forward.

Authors:  Azure N Faucette; Benjamin L Unger; Bernard Gonik; Kang Chen
Journal:  Hum Reprod Update       Date:  2014-07-11       Impact factor: 15.610

7.  Murine neonatal recent thymic emigrants are phenotypically and functionally distinct from adult recent thymic emigrants.

Authors:  Shannon J Opiela; Tulay Koru-Sengul; Becky Adkins
Journal:  Blood       Date:  2009-01-23       Impact factor: 22.113

Review 8.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

9.  T cells in the brain enhance neonatal mortality during peripheral LCMV infection.

Authors:  Laurie L Kenney; Erik P Carter; Anna Gil; Liisa K Selin
Journal:  PLoS Pathog       Date:  2021-01-05       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.